Biohaven Ltd
BHVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.05B
Close$
$-0.51
103.7% downside
Current Fair Value
103.7% downsideOvervalued by 103.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.05 Billion |
|---|---|
| Enterprise Value | $2.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.86 |
| Beta | 3.17 |
| Outstanding Shares | 150,636,620 |
Return
| Return on Equity | -4801.51% |
|---|---|
| Return on Assets | -158.29% |
| Return on Invested Capital | -190.14% |
Valuation & Multiples
| P/E Ratio | -2.94 |
|---|---|
| PEG | 9.56 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.6 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 24.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.76
Average shareholder expectationRevenue Estimate
$490,492
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.61
Average shareholder expectationRevenue Estimate
$70.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2047▼ 5.03% |
|---|---|
| Total Calls | 2,544,106▲ 24.13% |
| Total Puts | 520,800▼ 0.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.42%▼ 1.84% |
|---|---|
| Total Invested | $2.12B▲ 75.97% |
| Investors Holding | 310▲ 16.00% |
ESG Score
No data
About Biohaven Pharmaceutical Holding Company Ltd
CEO: Vlad Coric